These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 28667569

  • 1. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
    Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B, Caballero B, Zuddas A.
    CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
    [Abstract] [Full Text] [Related]

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 3. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC.
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [Abstract] [Full Text] [Related]

  • 4. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [Abstract] [Full Text] [Related]

  • 6. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
    Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K.
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):52-62. PubMed ID: 31814294
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Banaschewski T, Johnson M, Nagy P, Otero IH, Soutullo CA, Yan B, Zuddas A, Coghill DR.
    CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH, Greenbaum M, Arnold V, Yu M, Yan B, Jaffee M, Robertson B.
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
    Ginsberg L, Katic A, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Adler LA.
    Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
    Babcock T, Dirks B, Adeyi B, Scheckner B.
    BMC Pharmacol Toxicol; 2012 Dec 19; 13():18. PubMed ID: 23254273
    [Abstract] [Full Text] [Related]

  • 17. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC, Findling RL, Wu J, Kollins SH, Wang Y, Martin P, Robertson B.
    J Child Adolesc Psychopharmacol; 2020 Apr 19; 30(3):128-136. PubMed ID: 32233956
    [Abstract] [Full Text] [Related]

  • 18. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T, Brams M, Gasior M, Gao J, Giblin J.
    Postgrad Med; 2011 Mar 19; 123(2):169-76. PubMed ID: 21474905
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 19; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 20. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, Lopez FA.
    J Atten Disord; 2014 Feb 19; 18(2):123-32. PubMed ID: 22740112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.